MedDataX Logo

A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer

NCT ID: NCT01383863

Last Updated: 2019-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the protocol is to assess the rate of castration resistance, disease progression and overall survival over a 3-year period post-androgen deprivation therapy (ADT) induction in a study cohort of patients with advanced disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer

NCT02238366

Prostate Cancer
COMPLETED

Hormone Therapy in Treating Patients With Advanced Prostate Cancer

NCT00003026

Prostate Cancer
COMPLETED PHASE3

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NCT03516812

Castration-Resistant Prostate Carcinoma Prostate Adenocarcinoma
COMPLETED PHASE2

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

NCT01020448

Prostate Cancer
COMPLETED PHASE3

A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

NCT01957436

Metastatic Prostate Cancer
ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have participated and received study treatment in the Triptocare study
* Be aware of the investigational nature of this observational study cohort and must give written (personally signed and dated) informed consent

Exclusion Criteria

* Absence of written informed consent from the patient
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ipsen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ipsen Medical Director

Role: STUDY_DIRECTOR

Ipsen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fredericia Sygehus

Fredericia, , Denmark

Site Status

Frederiksbergs Hospital

Frederiksberg, , Denmark

Site Status

Herlev University Hospital

Herlev, , Denmark

Site Status

Odense Universitets Hospital

Odense, , Denmark

Site Status

Clinique Rhône Durance

Avignon, , France

Site Status

Hôpital Pellegrin

Bordeaux, , France

Site Status

CHU Henri Mondor

Créteil, , France

Site Status

Chru Lille

Lille, , France

Site Status

Hôpital Nord

Marseille, , France

Site Status

Clinique Beau Soleil

Montpellier, , France

Site Status

Private practice

Nancy, , France

Site Status

CHU Nantes

Nantes, , France

Site Status

CHU Pasteur

Nice, , France

Site Status

Hôpital Val de Grâce

Paris, , France

Site Status

Institut Mutualiste Monsouris

Paris, , France

Site Status

Hôpital Henry Gabrielle

Saint-Genis-Laval, , France

Site Status

Hôpital Foch

Suresnes, , France

Site Status

P.Stradins Clinical University Hospital

Riga, , Latvia

Site Status

Center of Oncology

Riga, , Latvia

Site Status

Medical University Clinics

Kaunas, , Lithuania

Site Status

University Hospital

Klaipėda, , Lithuania

Site Status

University Oncological Institute

Vilnius, , Lithuania

Site Status

Academisch Medisch Centrum

Amsterdam, , Netherlands

Site Status

Diaconessenhuis

Leiden, , Netherlands

Site Status

Medical Center

Arad, , Romania

Site Status

Sc E-Uro Srl

Cluj-Napoca, , Romania

Site Status

Oncomed

Timișoara, , Romania

Site Status

Ulster hospital

Belfast, , United Kingdom

Site Status

Bristol Royal Infirmary

Bristol, , United Kingdom

Site Status

Addenbrookes Hospital

Cambridge, , United Kingdom

Site Status

University Hospital Wales

Cardiff, , United Kingdom

Site Status

University Hospital Coventry

Coventry, , United Kingdom

Site Status

Leicester General Hospital

Leicester, , United Kingdom

Site Status

Nottingham City Hospital

Nottingham, , United Kingdom

Site Status

Lister Hospital

Stevenage, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark France Latvia Lithuania Netherlands Romania United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

http://clinicaltrials.gov/ct2/show/study/NCT01020448

Triptocare study NCT01020448

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

8-79-52014-187

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients
NCT03017313 COMPLETED
Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study
NCT02895230 COMPLETED
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
NCT01313273 TERMINATED PHASE3
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
NCT05458856 COMPLETED PHASE3
Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.
NCT04593420 COMPLETED
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
NCT01753297 COMPLETED PHASE4
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
NCT04181203 ACTIVE_NOT_RECRUITING PHASE3
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
NCT04523207 COMPLETED PHASE2
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
NCT01374087 TERMINATED PHASE2
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
NCT05100472 ACTIVE_NOT_RECRUITING PHASE2
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
NCT03516110 COMPLETED
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
NCT01715129 COMPLETED PHASE3
Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer
NCT01819285 COMPLETED PHASE3
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
NCT05169112 RECRUITING PHASE3
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
NCT01431391 COMPLETED PHASE2
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
NCT02175212 COMPLETED PHASE3
Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year
NCT00703768 UNKNOWN
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
NCT06473259 RECRUITING
Prostate Adenocarcinoma TransCutaneous Hormones
NCT00303784 UNKNOWN PHASE3
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
NCT06500741 COMPLETED
Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly
NCT00161252 WITHDRAWN
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
NCT00667069 COMPLETED PHASE3
Prostatic Cancer Versus Androgen Deficiency
NCT02235142 COMPLETED NA
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State
NCT01560858 COMPLETED
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
NCT03511196 ACTIVE_NOT_RECRUITING EARLY_PHASE1